High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
This study investigates the use of a high dose anti-VEGF agent for the treatment of radiation
retinopathy in those patients who have recalcitrant disease.